Mirna Therapeutics has appointed Yale University researcher Frank Slack as a scientific advisor.
Slack is currently an associate professor at Yale and focuses on the role of let-7 in cancer. He holds a PhD in molecular biology from Tufts University School of Medicine and a BSc from the University of Cape Town in South Africa.
Arrowhead Research, the parent company of Calando Pharmaceuticals, has named Ken Myszkowski as its CFO.
Myszkowski previously served as corporate controller for Broadwind Energy. Before that, he was controller for Epcor, a public energy company. He holds an MBA from the University of Chicago Booth School of Business.
Nektar Therapeutics has appointed Scott Greer to its board of directors.
Greer previously served as chairman of the board of Sirna Therapeutics, prior to its acquisition by Merck. Nektar's President and CEO Howard Robin was the former president and CEO of Sirna, and the company's COO Bharat Chowrira previously served as vice president at Sirna.